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Abstract
 
Using human autoimmune sera as molecular probes, we previously described the association of
phosphorylated serine/arginine splicing factors (SR splicing factors) with the U1-small nuclear
ribonucleoprotein (U1-snRNP) and U3-small nucleolar RNP (snoRNP) in apoptotic cells.
SR proteins are highly conserved autoantigens whose activity is tightly regulated by reversible
phosphorylation of serine residues by at least eight different SR protein kinase kinases (SRPKs),
including SRPK1, SRPK2, and the scleroderma autoantigen topoisomerase I. In this report,
we demonstrate that only one of the known SRPKs, SRPK1, is associated with the U1-snRNP
autoantigen complex in healthy and apoptotic cells. SRPK1 is activated early during apoptosis,
followed by caspase-mediated proteolytic inactivation at later time points. SRPKs are cleaved
in vivo after multiple apoptotic stimuli, and cleavage can be inhibited by overexpression of
bcl-2 and bcl-x
 
L
 
, and by exposure to soluble peptide caspase inhibitors. Incubation of recombi-
nant caspases with in vitro–translated SRPKs demonstrates that SRPK1 and SRPK2 are in
vitro substrates for caspases-8 and -9, respectively. In contrast, topoisomerase I is cleaved by
downstream caspases (-3 and -6). Since each of these SRPKs sits at a distinct checkpoint in the
caspase cascade, SRPKs may serve an important role in signaling pathways governing apoptosis,
alternative mRNA splicing, SR protein trafficking, RNA stability, and possibly the generation
of autoantibodies directed against splicing factors.
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Introduction
 
The breakdown of tolerance to self-antigens is a common
feature of autoimmune diseases including systemic lupus
erythematosus (SLE)
 
*
 
, systemic sclerosis, Sjögren’s syn-
drome, and mixed connective tissue disease (MCTD), re-
sulting in the production of autoantibodies (1). Accumulat-
ing data suggests that such a breakdown of tolerance may
be attributed to posttranslational modifications of autoanti-
gens during apoptosis or cellular stress, resulting in the cre-
ation of neoepitopes to which the immune system has
never been exposed or has been tolerized in the periphery
(2). A variety of apoptosis-specific posttranslational modifi-
cations has been described, including proteolysis by cas-
pases and granzyme B (3–6), and reversible phosphoryla-
tion/dephosphorylation of a subset of autoantigens (7, 8).
Autoimmune sera have proven to be very useful as mo-
lecular probes to study important biochemical processes
such as mRNA splicing, endoplasmic reticulum transport,
and apoptosis signaling. In addition to caspase cascades,
other signaling pathways are activated during apoptosis, in-
cluding the stress-activated protein kinase pathway (9).
Previously, we demonstrated that, in response to multiple
different apoptotic stimuli, serine/arginine splicing factors
(SR splicing factors) are reversibly phosphorylated during
apoptosis, and they physically associate with the U1-small
nuclear ribonucleoprotein (U1-snRNP) and U3-small nu-
cleolar ribonucleoprotein (U3-snoRNP) autoantigen com-
plexes (8, 10). Moreover, an SR protein kinase (SRPK) ac-
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Abbreviations used in this paper:
 
 CDK, cyclin-dependent kinase; DNA-
PK, DNA-dependent protein kinase; MCTD, mixed connective tissue
disease; NP40, nonidet P40; RNP, ribonucleoprotein; snRNP, small nu-
clear RNP; SLE, systemic lupus erythematosus; Sm, Smith complex; SR
splicing factor, serine/arginine splicing factor; SRPK, SR protein kinase. 
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tivity was found to coprecipitate with the U1-snRNP
using human sera derived from patients with SLE or
MCTD, although the SRPK was not identified in our ini-
tial reports (7, 8).
In this study, we demonstrate that one of the major
known SRPKs, SRPK1, is physically associated with the
U1-snRNP autoantigen complex in cells and can be im-
munoprecipitated using mAbs directed against U1-snRNP
components or SR proteins, as well as human serum de-
rived from patients with SLE or MCTD. Moreover, three
different SRPKs (SRPK1, SRPK2, and topoisomerase I)
are differentially cleaved by recombinant caspases in vitro,
and in vivo in several different cells lines. SRPK1 is acti-
vated and phosphorylates the SR protein ASF/SF2 at an
early stage of apoptosis, before cleavage by caspases, while
the SRPK1 and SRPK2 cleavage products lack kinase ac-
tivity. These results suggest that SRPK1 and perhaps other
SRPKs are activated during cell stress and that the fidelity
of the apoptosis program is assured through caspase-medi-
ated cleavage of SRPKs that sit at “apoptosis checkpoints.”
These results have important implications for understand-
ing molecular mechanisms underlying alternative splicing
regulation, apoptosis signaling, and the generation of au-
toantibodies in SLE and MCTD.
 
Materials and Methods
 
Cell Culture.
 
Jurkat cells or human MCF7 breast carcinoma
cells were grown in 5% CO
 
2
 
 at 37
 
 
 
C using RPMI 1640 (Bio
Whittaker) supplemented with 9% heat-inactivated fetal calf se-
rum (HI-FCS; Bio Whittaker) and penicillin and streptomycin
(GIBCO BRL). Cells were grown and harvested at mid-log
phase. Adherent cells were plated the night before each experi-
ment such that cells were at 50–80% confluence on the day of the
experiment. Jurkat cells engineered to stably overexpress bcl-2
(or empty vector), a gift from J.C. Reed (La Jolla Cancer Re-
search Foundation, La Jolla, CA), or MCF7 cells engineered to
stably overexpress bcl-x
 
L
 
 (or empty vector), a gift from N. Ked-
ersha (Brigham & Women’s Hospital, Boston, MA) were grown
in RPMI 1640 medium as described above, supplemented with
G418 (GIBCO BRL) at a final concentration of 500 
 
 
 
g/ml.
Overexpression was confirmed by Western blot analysis.
 
Cell Lysis.
 
Jurkat cells or MCF7 cells were solubilized in
Nonidet P40 (NP40) lysis buffer (1% NP-40, 150 mM NaCl, 50
mM Tris, pH 7.8, 1 mM EDTA, and a protease inhibitor cocktail
described previously; reference 11) or detergent lysis buffer (50
mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% vol/vol NP-40, 5
mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM
sodium pyrophosphate, 10 mM benzamidine, 100 
 
 
 
g/ml PMSF,
10 
 
 
 
g/ml 
 
N
 
-tosyl-phenylalanine chloromethyl ketone, 10 
 
 
 
g/ml
soybean trypsin inhibitor, 1 
 
 
 
g/ml aprotinin, 1 
 
 
 
g/ml leupeptin
prepared as described previously; reference 16). All chemicals
were purchased from Sigma-Aldrich. After addition of lysis
buffer, cells were incubated on ice for 30 min, centrifuged in a
refrigerated microfuge (Biofuge Fresco, Kendro Laboratory, Ha-
nau, Germany) at 13,000 rpm for 15 min, and the supernatant
was used immediately for each experiment. MCF7 cells were
trypsinized, washed with PBS, and lysed as described above.
Identical results were obtained in other experiments performed
by scraping cells from plates in the absence of trypsin.
 
UV Irradiation.
 
Jurkat cells were plated in 100 
 
 
 
 15 mm
polystyrene petri dishes (Nunc) at a concentration of 2 
 
  
 
10
 
6
 
cells/ml and irradiated in a Stratalinker 2400 (Stratagene) at a dis-
tance of 9 cm for 30 s (6). After irradiation, cells were incubated
at 37
 
 
 
C for the indicated times before harvesting.
 
Cellular Activation.
 
Jurkat cells were treated with anti-Fas an-
tibody 7C11 (IgM; provided by M. Robertson, Indiana Univer-
sity, Bloomington, IN) from hybridoma supernatants at a final di-
lution of 1:500. Cells were incubated at 37
 
 
 
C for the indicated
times before harvesting. For experiments using caspase inhibitors,
Jurkat cells were pretreated for 1 h at 37
 
 
 
C with either 10 
 
 
 
M
ZVAD-fmk or 10 
 
 
 
M DEVD-fmk (Kamiya Biomedical Co.;
reference 6). After 1 h, apoptosis was induced by the addition of
7C11, and the cells were processed as described above. Jurkat
cells or MCF7 cells were treated with 10 
 
 
 
g/ml anisomycin or 2
 
 
 
M staurosporine (Sigma-Aldrich) for varying times before har-
vesting, and the cells were processed as described previously.
 
Plasmid Construction and Preparation of Recombinant ASF/SF2.
 
cDNA clones encoding human SRPK1 and SRPK2 (SRPKs)
were provided by X.D. Fu (UCSD School of Medicine, La Jolla,
CA). Mouse SRPKs were provided by M. Hagiwara (Tokyo
Medical and Dental University, Tokyo, Japan). Human Clk/Sty
1–4 have been described previously and were provided by O.
Nayler, Max-Planck-Institute for Biochemistry, Martinsried,
Germany (12). Epitope-tagged ASF/SF2 was constructed by
PCR amplification using a human ASF/SF2 construct as a tem-
plate, provided by A.R. Krainer (Cold Spring Laboratory, Cold
Spring Harbor, NY). Primer sequences were as follows: sense
primer, 5
 
 
 
-GAGAGAGGATCCGTCGGGAGGTGGTGTGA-
TT-3
 
 
 
; and anti-sense primer, 5
 
 
 
-GAGAGAAAGCTTTGTAC-
GAGAGCGAGATCT-3
 
 
 
. The PCR product was then cloned
in-frame into pTriEx-4 (Novagen) using the restriction enzymes
BamHI and HindIII, and the constructs were sequence-verified
for both strands. His-tagged ASF/SF2 was expressed in 
 
Escherichia
coli
 
 Origami (DE3) pLacI (Novagen) with IPTG induction, ex-
tracted using a Ni-NTA Spin kit (QIAGEN), analyzed by BCA
protein assay (Pierce Chemical Co.), Coomassie staining, and
Western blotting using antibodies specific for both His-C tag (In-
vitrogen), and HSV tag (Novagen), respectively.
 
In Vitro Transcription/Translation.
 
[
 
35
 
S] methionine-labeled p35,
IL-1
 
 
 
, Ich-1, mouse SRPKs, human SRPKs, or Clk/Sty kinases
1–4 were in vitro transcribed and translated using the TNT rabbit
reticulocyte lysate kit (Promega), according to the manufacturer’s
instructions. Reactions were performed using 0.25 
 
 
 
g plasmid in
a 10 
 
 
 
l transcription/translation reaction mixture containing 0.5
 
 
 
l of translation grade [
 
35
 
S] methionine (7.9 
 
 
 
Ci/ml; NEN Life
Science Products, Inc.).
 
In Vitro Caspase Cleavage Assays.
 
In vitro–translated proteins
synthesized as described previously were incubated in caspase
cleavage buffer with recombinant caspases (caspases 1, 2, 3, 8, 9,
or a control bacterial lysate) for 90 min at 30
 
 
 
C as described pre-
viously (6). cDNAs encoding individual caspases were a gift of H.
Li and J. Yuan (Harvard Medical School, Boston, MA). The data
for caspase-8 cleavage of SRPK1 was confirmed using recombi-
nant, purified His-tagged caspase-8 (Sigma-Aldrich). Recombi-
nant caspases were prepared as described and frozen at 
 
 
 
80
 
 
 
C
until used (6). In a separate reaction, the mixture was then sepa-
rated by SDS-PAGE, transferred to nitrocellulose (OSMONICS)
and exposed for autoradiography. In separate experiments, each
caspase was incubated with in vitro–translated proteins including
p35 (a gift of V. Shifrin, Scriptgen, Inc., Medford, MA), pro-
caspase 2, or IL-1
 
 
 
 (gifts of H. Li and J. Yuan, Harvard Medical
School) to confirm their activity (unpublished data). 
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Immunoprecipitation and Western Blot Analysis.
 
Lysates were pre-
cleared once with 100 
 
 
 
l of a 50% solution of protein A-Sepha-
rose (Amersham Pharmacia Biotech) in detergent lysis buffer and
5 
 
 
 
g rabbit anti–mouse IgG (Jackson ImmunoResearch Labora-
tories) for 1–2 h. Mouse mAbs (2–5 
 
 
 
g monoclonal and 5 
 
 
 
g
rabbit anti–mouse IgG) were used as follows: anti-SRPK1 and
anti-SRPK2 (Transduction Laboratories); anti-cdc2 (cyclin-depen-
dent kinase [CDK]1; Santa Cruz Biotechnology, Inc.); anti-SC35
(Sigma-Aldrich); and anti-U2B
 
 
 
 (4G3, a gift of W.J. van Ven-
rooij, University of Nijmegan, Nijmegen, The Netherlands) (13).
Human autoimmune serum samples were employed as follows: 3
 
 
 
l human polyclonal anti–Scl-70 or anti–U1-snRNP (Immuno-
vision). U1-snRNP-specific sera that were previously shown to
coprecipitate SR proteins and control sera have been described
previously (7, 8). 2 
 
 
 
l anti–
 
D
 
NA-dependent protein kinase
(DNA-PK
 
CS
 
) (Serotec) was used for IP kinase and Western blot-
ting experiments. Immunoprecipitations were performed after
addition of detergent lysis buffer to a total volume of 500 
 
 
 
l, and
rotation in a 4
 
 
 
C cold room for 2–4 h. Precipitates were har-
vested by centrifuging for 20 s at 12,000 rpm in a refrigerated
Heraeus microfuge, washing three times with detergent lysis
buffer, resuspending in SDS loading buffer with 9% 2-mercapto-
ethanol, boiling for 5 min, and separating by SDS-PAGE as de-
scribed previously (6). Proteins were transferred to nitrocellulose
for Western blotting experiments. Antibodies and dilutions used
were as follows: anti-cdc2 (CDK1) (1:100; Santa Cruz Biotech-
nology, Inc.); anti–DNA-PK
 
CS
 
 (1:3,000; Serotec); anti-SRPKs
(1:1,000; Transduction Laboratories); anti-topoisomerase I (1:100;
Arthritis Foundation/CDC Reference Sera); anti–bcl-2 (1:100;
BD PharMingen); anti–bcl-x
 
L
 
 (1:400; Santa Cruz Biotechnology,
Inc.); anti–phospho-cdc2 (CDK1)/Tyr-15 (1:500; New England
BioLabs); anti-PARP (1:500; Transduction Laboratories); mAb104
(1:5 dilution of hybridoma supernatants, a gift of R. Reed, Har-
vard University School of Medicine); and anti-Smith complex
(Sm) (1:50; Immunovision). Nitrocellulose filters were blocked
with 5% Blotto (Bio-Rad Laboratories) in PBS overnight at 4
 
 
 
C.
Bands were visualized using species-specific antibody conjugated
to HRP (Amersham Pharmacia Biotech) at a dilution of 1:7,500
in 5% Blotto in PBS, and developed using ECL chemilumines-
cence performed according to the manufacturer’s instructions
(Amersham Pharmacia Biotech).
 
Immunoprecipitation Kinase Assays.
 
Immunoprecipitation kinase
assays have been described previously (7, 14–16). For cdc2
(CDK1) kinase assays, individual precipitates were washed three
times in detergent lysis buffer and once in wash buffer A: (50 mM
Tris-HCl, pH 7.4, 10 mM MgCl
 
2
 
), resuspended in 20 
 
 
 
l reaction
buffer A: (50 mM Tris, pH 7.4, 10 mM MgCl
 
2
 
, 2.0 
 
 
 
M ATP)
containing 5 
 
 
 
Ci [
 
 
 
-
 
32
 
P] ATP, 125 
 
 
 
g/ml Histone H1 for cdc2
(CDK1)/Histone H1; (kinase/substrate) or 10 
 
 
 
Ci [
 
 
 
-
 
32
 
P] ATP,
25 pmoles bacterial ASF/SF2 for cdc2 (CDK1)/ASF/SF2 (ki-
nase/substrate), then incubated at 30
 
 
 
C for 10 min, or at 30
 
 
 
C for
30 min, respectively (16). For DNA-PK
 
CS
 
 kinase assays, individ-
ual precipitates were washed three times in detergent lysis buffer
and once in wash buffer B (50 mM Tris, pH 7.4, 5 mM MnCl
 
2
 
),
resuspended in 20 
 
 
 
l of reaction buffer B (50 mM Tris, pH 7.4, 5
mM MnCl
 
2
 
, 5 mM DTT, 5 mM NaF, 40 
 
 
 
M MgCl
 
2
 
, 1 mM so-
dium orthovanadate, 4 
 
 
 
M ATP, 50 
 
 
 
g/ml salmon sperm DNA)
containing 10 
 
 
 
Ci [
 
 
 
-
 
32
 
P] ATP, 20 
 
 
 
g 
 
 
 
-casein, then incubated
at 30
 
 
 
C for 15 min (14). For SRPK1, SRPK2, and topoisomerase
I kinase assays, individual precipitates were washed three times in
detergent lysis buffer and once in wash buffer C (40 mM Hepes,
pH 7.5, 120 mM NaCl), resuspended in 20 
 
 
 
l of reaction buffer
C (40 mM Hepes, pH 7.5, 120 mM NaCl, 2 mM DTT, 10 mM
 
MgCl
 
2
 
, 2 mM benzamidine, 20 
 
 
 
M ATP) containing 10 
 
 
 
Ci [
 
 
 
-
 
32
 
P] ATP, 25 pmoles bacterial ASF/SF2, then incubated at 30
 
 
 
C
for 30 min (15). All kinase reactions were terminated by boiling
in equal volume of 2
 
 
 
 SDS loading buffer. Proteins were sepa-
rated by SDS-PAGE and transferred to nitrocellulose. The extent
of phosphorylation of individual substrates was detected by auto-
radiography, then quantified using Molecular Imager
 
®
 
 FX (Bio-
Rad Laboratories). The extent of phosphorylation was deter-
mined by subtracting background counts (CPM/mm
 
2
 
) from total
counts (CPM/mm
 
2
 
). The results depict the means of three repre-
sentative experiments. In some experiments, individual immuno-
precipitates were washed three times in detergent lysis buffer and
once in wash buffer C, then incubated in 20 
 
 
 
l of reaction buffer
C containing 20 
 
 
 
Ci [
 
 
 
-
 
32
 
P] ATP at 30
 
 
 
C for 30 min (15).
 
Dissociation of SRPK1 from Immunoprecipitate by 1 M MgCl
 
2
 
.
 
The effect of antibody binding on the dissociation of SRPK1
from the immunoprecipitate was investigated by including 1 M
MgCl
 
2
 
 in the buffers, either before or after the binding of anti-
bodies to proteins in the lysate had occurred (17).
For one set of immunoprecipitations, 10–13 million Jurkat
cells were solubilized in NET/NP40 buffer (150 mM NaCl, 2
mM EDTA, and 50 mM Tris-HCl, pH 7.5 [NET], and 0.3%
NP-40) containing 0.5 mM PMSF and 1 
 
 
 
g/ml aprotinin. Ly-
sates were then precleared, and immunoprecipitations were per-
formed as described previously. Immunoprecipitates were washed
three times with 0.5 M NaCl NET (standard immunoprecipita-
tion), or washed twice with 1 M MgCl
 
2
 
 NET/NP40, and once
with NET. The other set of immunoprecipitations was per-
formed in an identical manner using extracts prepared from cells
lysed in 1 M MgCl
 
2
 
 NET/NP40.
 
Results
 
Autoimmune Sera Derived from MCTD and SLE Patients
Coprecipitate SRPK1 and SR Splicing Factors. Thus far, eight
kinases have been reported to have the capacity to phos-
phorylate SR proteins, including SRPK1 and SRPK2,
Clk/Sty kinases 1–4, topoisomerase I (Scl-70), and cdc2
(CDK1) (12, 15, 18–20). SRPK1 is the best characterized
of these kinases and is known to phosphorylate several
different SR proteins including SRp55 (pp54), SC35,
ASF/SF2, SRp20 (pp23), and U2AF65 (21). Previously,
we demonstrated that autoimmune sera derived from pa-
tients with SLE, overlap syndromes, and MCTD pre-
cipitate at least seven distinct phosphoproteins (desig-
nated pp200, pp54, pp46, pp42, pp34, pp23, and pp17)
from apoptotic Jurkat cell lysates, as well as an unidentified
kinase activity (7, 8). We went on to demonstrate that
pp54, pp42, pp34, and pp23 are SR proteins that associate
directly with the U1-snRNP and U3-snoRNP during ap-
optotic stress (8, 10). We hypothesized that one or more
of the eight known SRPKs was a component of the spli-
ceosome and was responsible for the SRPK activity we
observed in vitro. To test this hypothesis, we repeated the
in vitro kinase assays reported previously, using human se-
rum specific for the U1-snRNP complex (7, 8). The im-
munoprecipitates were then analyzed by Western blot as-
says using antibodies specific for individual SRPKs. As
shown in Fig. 1, Jurkat cells were incubated for the time
indicated above the panels in the presence of anti-Fas,1216 Identification of an Autoantigen Kinase Signaling Pathway
which engages and activates the Fas death receptor, then
solubilized in detergent lysis buffer. Proteins were immu-
noprecipitated using the indicated sera or antibodies, and
subjected to in vitro phosphorylation kinase assays (Fig. 1
A). As expected, U1-snRNP specific human sera, but not
a mAb specific for a U2-snRNP component, U2B, pre-
cipitate SR proteins (pp54, pp46, pp42, pp34, and pp23)
from apoptotic Jurkat cell lysates (Fig. 1 A). Over 40 other
autoimmune sera specific for autoantigens other than the
U1-snRNP failed to coprecipitate SR proteins, suggesting
that members of the SR splicing factor family uniquely as-
sociate with the U1-snRNP during apoptosis (reference 8,
and unpublished data). We next performed Western blot-
ting of the membranes using antibodies specific for indi-
vidual SRPKs. Surprisingly, all of the U1-snRNP-specific
serum samples precipitated SRPK1 (lanes numbered 1,
Fig. 1 B). SRPK1 was not precipitated using control sera,
using sera from patients with other autoimmune diseases,
or using a U2-snRNP specific mAb (Fig. 1 B and unpub-
lished data). SRPK2, topoisomerase I, and cdc2 (CDK1)
were not present in the immunoprecipitates (unpublished
data), suggesting that SRPK1 is the major SRPK associ-
ated with the U1-snRNP autoantigen complex, the major
target antigen in patients with MCTD. When lysates were
prepared from apoptotic Jurkat cells (lanes numbered 2),
SRPK1 was less abundant (e.g., U1-snRNP and B83, left
panels of Fig. 1 B) or nearly completely absent (e.g., L41
and SLE 7, middle panels of Fig. 1 B) from the immuno-
precipitates, and a 66-kD protein was recognized by
SRPK1-specific antibodies. This result suggests that
SRPK1 is cleaved in vivo during apoptosis, and that at
least one of the cleavage fragments remains associated with
the U1-snRNP autoantigen complex.
SRPK1 Is Associated with the U1-snRNP but Is Not Di-
rectly Recognized by Serum Autoantibodies. From the exper-
iments shown in Fig. 1, it is not clear whether SRPK1 is
recognized directly by serum autoantibodies, or whether
the kinase is coprecipitated through noncovalent interac-
tions with other components of the U1-snRNP (which are
themselves directly recognized by serum autoantibodies).
To address this question, we included 1 M MgCl2 in sev-
eral of the buffers. In studies of the interaction between an-
tibodies and snRNPs, high concentrations of MgCl2 have
been shown to dissociate weak, noncovalent interactions
between proteins, but not interactions between antibody
and antigen(s) (17, 22). Jurkat cell lysates prepared in NET/
NP40 were immunoprecipitated with autoimmune and
control sera (Fig. 2), in the presence (lanes numbered 2 and
3) or absence (lanes numbered 1) of 1 M MgCl2. Individual
precipitates were analyzed by IP/Western blot as described
in Materials and Methods. As expected, SRPK1 is still de-
tected by Western blot analysis when anti-SRPK1 is used
to perform the immunoprecipitation (Fig. 2 A). However,
SRPK1 is not detected in MgCl2-treated immunoprecipi-
tates prepared using a prototypic human U1-snRNP/
Smith serum (Fig. 2 B) or a mAb directed against the SR
splicing factor SC35 (Fig. 2 D). The Sm proteins B/B  are
retained in the immunoprecipitate (Fig. 2 C), demonstrat-
Figure 1. U1-snRNP specific sera derived from patients with SLE and MCTD coprecipitate SRPK1 from Jurkat cell lysates. (A) Jurkat cells were in-
cubated in the presence of anti-Fas for the time indicated at the top of each figure, solubilized in detergent lysis buffer, and antigens precipitated using hu-
man U1-snRNP specific serum (Immunovision), anti-U2B  (mouse monoclonal supernatant 4G3), or human serum (MCTD patient sera: B83, L41,
SLE patient serum: SLE 7), and control). Individual precipitates were subjected to an in vitro kinase assay. Bands corresponding to pp46, pp42, pp34, and
pp23 are shown on the right side of the panels (top panel). (B) Precipitated proteins were analyzed by IP/Western blot analysis with anti-SRPK1 (mouse
monoclonal). Full-length SRPK1 and cleavage products are shown on the right sides of the panels (bottom panel).1217 Kamachi et al.
ing that treatment with MgCl2 did not disrupt direct anti-
body–antigen interactions. These results demonstrate that
SRPK1 is coprecipitated via intermolecular binding inter-
actions with components of the U1-snRNP complex, and
is not directly recognized by serum autoantibodies. Identi-
cal results were obtained using serum samples presented in
Fig. 1 (unpublished data).
SRPK1 and SRPK2 Are Differentially Cleaved by Caspases
In Vitro and In Vivo. Previous studies have demonstrated
that an SRPK (topoisomerase I) is cleaved by caspases-3
and -6 at unconventional sites during apoptosis (23). The
results shown in Fig. 1 further suggested that another
SRPK (SRPK1), and perhaps other SRPKs, may also un-
dergo proteolysis during apoptosis. We tested this hypothe-
sis by using a well-validated in vitro cleavage assay using re-
combinant caspases. In vitro–transcribed/translated SRPKs
were incubated in caspase cleavage buffer in the presence of
recombinant caspases or a control bacterial lysate, separated
by SDS-PAGE and analyzed by autoradiography. As
shown in Fig. 3, A and B, human SRPK1 and SRPK2
are differentially cleaved by recombinant caspase-8 and
caspase-9, respectively, yielding signature  66-kD and 34-
kD fragments (SRPK1) and 80-kD and 50-kD fragments
(SRPK2), respectively. None of the other caspases tested
had the ability to cleave SRPK1 and SRPK2, although
caspase-1 appeared to partially cleave human SRPK1, gen-
erating fragments of identical size to those observed with
caspase-8 (lane 2). Mouse SRPK1 and SRPK2, which are
92 and 58% conserved between mouse and man, respec-
tively, were also differentially cleaved by caspase-8 and
caspase-9, respectively, generating fragments of approxi-
mately the same molecular weight (unpublished data). In
contrast, none of the Clk/Sty isoforms was cleaved by re-
combinant caspases (unpublished data). Taken together
with the published data on topoisomerase I, these results
demonstrate that at least 3 of the 8 known SRPKs are dif-
ferentially cleaved by caspases.
Next, we examined whether SRPKs undergo proteolysis
during apoptosis in vivo. We used Jurkat cells treated with
7C11(anti-Fas) mAb, a well-established model system for
apoptosis. Jurkat cells were incubated with anti-Fas for var-
ious times over a 6-h period. Western blot analysis of cell
lysates was performed with anti-SRPK1, anti-SRPK2,
anti-topoisomerase I, and anti-cdc2 (CDK1). As shown in
Fig. 4, A and B, cleavage products of SRPK1 and SRPK2
are first detectable 2 h after anti-Fas addition. After 4 h,
smaller fragments generated by further degradation were
also observed for SRPK2 (Fig. 4 B). The cleavage frag-
Figure 2. SRPK1 is not rec-
ognized directly by human se-
rum autoantibodies. Jurkat cell
lysates were immunoprecipi-
tated with anti-SRPK1, anti-
SC35, and human U1-snRNP
specific serum (Immunovision).
Immunoprecipitates were
washed using standard condi-
tions (0.5 M NaCl washing,
lane 1), or with 1 M MgCl2
treatment either after (lane 2) or
before (lane 3) incubation with
anti-SRPK1, anti-SC35, or anti-U1-snRNP specific serum. Retention of SRPK1 or U1-snRNP components on the beads was confirmed by immu-
noblotting with anti-SRPK1 and human Sm specific serum (Immunovision).
Figure 3. Human SRPK1 and
SRPK2 are differentially cleaved
by recombinant caspases in vitro.
SRPK1 and SRPK2 were syn-
thesized by in vitro transcrip-
tion/translation and incubated
with the recombinant caspases
indicated by number at the top
of each figure. Proteins were
separated by SDS-PAGE, trans-
ferred to nitrocellulose, and de-
tected by autoradiography. The
relative migration of molecular
size markers in kilodaltons is in-
dicated on the left side of each
panel. Lanes are numbered at the
bottom of each panel.1218 Identification of an Autoantigen Kinase Signaling Pathway
ments detected by Western blot analysis (Fig. 4, A and B)
comigrate precisely with the fragments observed in the in
vitro caspase cleavage assay using recombinant caspases
(Fig. 3, A and B), suggesting that SRPK1 and SRPK2 are
differentially cleaved in vivo by caspases-8 and -9, respec-
tively. Only a partial cleavage fragment of topoisomerase I
migrating at 75-kD was detected, beginning at a later time
point (4 h, Fig. 4 C). Cleavage of cdc2 (CDK1) was not
detected (Fig. 4 D). These results demonstrate that SRPK1,
SRPK2, and topoisomerase I are cleaved in vivo during
Fas-mediated apoptosis, further suggesting that (i) SRPK1,
SRPK2, and topoisomerase I may play important roles in
apoptosis and/or stress signaling pathways and (ii) their
proteolytic cleavage during apoptosis may alter or modulate
their ability to function as kinases.
SRPK1 and SRPK2 Are Cleaved after Multiple Different
Apoptotic Stimuli. To determine whether cleavage of
SRPK1 and SRPK2 was specific to Fas-induced apoptosis,
Jurkat cells were treated in the absence (Fig. 5, A and B,
lane 1 M) or presence of anti-Fas (lane 2 F), the antibiotic
anisomycin (lane 3; Fig. 5 A), staurosporine, a broad-spec-
trum protein kinase inhibitor (lane 4 S, reference 24), or
UV irradiation (lane 5 U). Cells were harvested after 6 h
and processed as described in Materials and Methods. All
four stimuli induced the cleavage of SRPK1 and SRPK2,
yielding the 66-kD (SRPK1) and 50-kD (SRPK2) frag-
ments, respectively. An additional degradation product mi-
grating at 35 kD (for SRPK2) is also detectable (Fig. 5 B,
lanes 2–5).
Proteolytic Cleavage of SRPKs Is Prevented by Ectopic Ex-
pression of bcl-2, bcl-xL, and Preincubation with Small Peptide
Caspase Inhibitors. Next, we asked whether the cleavage
of SRPK1 or SRPK2 could be inhibited by overexpression
of bcl-2 or bcl-xL both of which prevent apoptosis induced
by multiple stimuli, including   irradiation and UV irradia-
tion (25–28), or by the addition of small peptide caspase in-
hibitors. Jurkat cells stably transfected with either empty
vector (Fig. 6 A, lanes 5–8) or bcl-2 (Fig. 6 A, lanes 1–4)
were subjected to UV irradiation. MCF7 cells stably trans-
fected with either empty vector (Fig. 6 B, lanes 5–8) or
bcl-xL (Fig. 6 B, lanes 1–4) were incubated with anisomy-
cin. Cells were solubilized, and lysates were separated by
Figure 5. SRPK1 and SRPK2 are cleaved in vivo after multiple differ-
ent apoptotic stimuli. Jurkat cells were subjected to various apoptotic
stimuli and harvested for protein analysis by NP-40 lysis after 6 h. Lysates
were separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis using anti-SRPK1 (top panel) or anti-SRPK2
(bottom panel). The relative migration of molecular size markers in kilo-
daltons is indicated on the left side of the panel. SRPK1 and SRPK2
cleavage products are shown on the right side of each panel. The stimulus
is indicated above the panel as follows: mock treatment (M), anti-Fas
7C11 (F), anisomycin (A), staurosporine (S), and ultraviolet irradiation
(U). Lanes are numbered at the bottom of each panel.
Figure 4. SRPK1 and SRPK2 are cleaved during Fas-mediated apop-
tosis in vivo. Jurkat cells were incubated with 7C11(anti-Fas) over a 6-h
time period and harvested by NP-40 lysis at the times indicated at the top
of each figure (in hours). Lysates were separated by SDS-PAGE, trans-
ferred to nitrocellulose, and subjected to Western blot analysis using anti-
SRPK1 (A), anti-SRPK2 (B), anti-topoisomerase I: arthritis foundation/
CDC reference sera (C), and anti-cdc2 (CDK1) (mouse monoclonal) (D).
The relative migration of molecular size markers in kilodaltons is indi-
cated on the left side of each panel. SRPK1, SRPK2 and topoisomerase I
cleavage products are shown on the right side of the panel. Lanes are
numbered at the bottom of each panel.1219 Kamachi et al.
SDS-PAGE, transferred to nitrocellulose, and blotted with
antibodies specific for SRPK1 (top panels) or SRPK2 (bot-
tom panels). SRPK cleavage products were observed in
Jurkat (neo) control cells in response to UV irradiation
(Fig. 6 A, lanes 5–8) as well as MCF7 (neo) control cells in
response to addition of anisomycin (Fig. 6 B, lanes 5–8),
respectively. Cleavage products were absent from Jurkat
(bcl-2) transformants (Fig. 6 A, lanes 1–4) as well as MCF7
(bcl-xL) transformants (Fig. 6 B, lanes 1–4), suggesting that
cleavage of SRPKs is downstream of the inhibitory effects
of bcl-2 and bcl-xL. Interestingly, SRPK2 in MCF-7 cells
migrated at  130–140 kD (rather than at  120 kD, as ob-
served in Jurkat cells, Fig. 4), suggesting that a novel
SRPK2 isoform exists in MCF7 cells. The functional im-
portance of this observation is under investigation.
To determine if caspases are required for cleavage of
SRPK1 and SRPK2, Jurkat cells were cocultured with
ZVAD (a soluble pan-caspase inhibitor) (Fig. 6 C, lane 3), or
DEVD (a soluble peptide inhibitor of CPP32 family pro-
teases; reference 29) (Fig. 6 C, lane 4), for 1 h before the ad-
dition of anti-Fas. 5 h later, cells were solubilized, and lysates
were separated by SDS-PAGE, transferred to nitrocellulose,
and blotted with anti-SRPK1 or SRPK2. Both inhibitors
effectively prevented the appearance of cleavage products
(Fig. 6 C, lanes 3 and 4), indicating that caspases are required
for cleavage of SRPK1 and SRPK2, respectively.
SRPK1 Kinase Activity Is Activated during Fas-mediated Ap-
optosis. Dozens of signaling molecules are regulated dur-
ing apoptosis, with varying outcomes. For example, some
kinases are activated (e.g., MEKK-1 and PKC- ), while
others are inactivated (e.g., DNA-PKCS and Wee-1) or re-
localized (e.g., fyn) to other cellular compartments after
cleavage by caspases and other proteases (for a review, see
reference 30). To determine whether any of the known
SRPKs are activated during apoptosis, we performed im-
munoprecipitation kinase assays from lysates prepared from
Figure 6. Cleavage of SRPK1 and SRPK2 is inhibited in vivo by overexpression of bcl-2
or bcl-xL, and by coincubation with specific caspase inhibitors. (A) SRPK cleavage is inhibited
in Jurkat cells overexpressing bcl-2. Jurkat (bcl-2) transformants (lanes 1–4) and Jurkat (neo)
control transformants (lanes 5–8) were subjected to UV irradiation, then cultured for the times
indicated above each lane (in hours) and solubilized in NP-40 lysis buffer. Proteins were sepa-
rated by SDS-PAGE and transferred to nitrocellulose. The membrane was then blotted with
anti-SRPK1 (top panel) or anti-SRPK2 (bottom panel). (B) SRPK cleavage is inhibited in
MCF7 cells overexpressing bcl-xL. MCF7 bcl-xL transformants (lanes 1–4) and MCF7 (neo)
control transformants (lanes 5–8) were treated with anisomycin, cultured for the times indi-
cated above each lane (in hours) and solubilized in NP-40 lysis buffer. Proteins were separated
by SDS-PAGE and transferred to nitrocellulose. The membrane was then blotted with anti-
SRPK1 (top panel) or anti-SRPK2 (bottom panel). (C) SRPK cleavage is inhibited by coincubation with small peptide caspase inhibitors. Jurkat cells
were preincubated for 1 h with the indicated specific caspase inhibitors, cultured with anti-Fas, and harvested 5 h later for protein analysis. The mem-
brane was blotted with anti-SRPK1 (top panel) or anti-SRPK2 (bottom panel). The stimulus is indicated above the panel as follows: mock treatment
(M), anti-Fas 7C11 with no pretreatment (F), pretreatment with ZVAD-fmk (Z), and pretreatment with DEVD-fmk (D). The relative migration of mo-
lecular size markers in kilodaltons is indicated on the left side of the panel. SRPK1 and SRPK2 cleavage products are shown on the right side of the
panel. Lanes are numbered at the bottom of each panel.1220 Identification of an Autoantigen Kinase Signaling Pathway
healthy or apoptotic Jurkat T cells, as described in detail in
Materials and Methods. SRPKs were immunoprecipitated
with anti-SRPK1, anti-SRPK2, anti–Scl-70 (topoisom-
erase I), or anti-cdc2 (CDK1), respectively. Precipitates
were washed extensively, and the activity of individual ki-
nases was determined by the ability of the kinase to phos-
phorylate known kinase substrates, including recombinant
ASF/SF2 and purified Histone H1. As previously reported,
the histone H1 kinase activity associated with cdc2 (CDK1)
increases nearly threefold during Fas-mediated apoptosis
(Fig. 7 A) (31). In contrast, the ability of cdc2 (CDK1) or
topoisomerase I to phosphorylate ASF/SF2, either in
healthy cells or dying cells, is negligible. ASF/SF2 is effi-
ciently phosphorylated by both SRPK1 and SRPK2 when
immunoprecipitations are performed using lysates prepared
from healthy cells (left side of panel). However, of these
two SRPKs, only SRPK1 exhibits an increase in ASF/SF2
kinase activity in response to an apoptotic stimulus (Fig. 7,
left side of panel A). Analysis of the immunoprecipitates re-
veals that an SRPK1 cleavage product is readily detectable
2 h after anti-Fas treatment (Fig. 7 B, IP/Western blot
analysis), yielding the signature 66-kD fragment. Small
amounts of cleavage products (arrow heads) were detect-
able for SRPK2 and topoisomerase I. The level of cdc2
Figure 7. SRPK1 is activated and phosphorylates the SR protein autoantigen ASF/SF2 during apoptosis. Jurkat cells were incubated with anti-Fas and
harvested in detergent lysis buffer at the times indicated at the top of each panel (in hours). SRPK1, SRPK2, topoisomerase I, and cdc2 (CDK1) activities
were assayed by immunoprecipitation assays using purified kinase-specific substrates as described in Materials and Methods. Each kinase activity was assayed
using 0.5 mg of cytosolic protein and 25 pmoles of bacterial ASF/SF2 or 5  g of Histone H1. The extent of phosphorylation of individual substrates was
detected by autoradiography, and quantified using Molecular Imager®FX (Bio-Rad Laboratories). Individual phosphorylation (CPM/mm2) is indicated as
shown in A. Precipitated full-length protein (black arrow) and cleavage product (arrow head) were analyzed by IP/Western blot in the middle panels.
Cleavage of PARP (bottom panel), as well as dephosphorylation of cdc2 (Tyr-15), (bottom panel) was also analyzed.1221 Kamachi et al.
(CDK1) remains the same during Fas-induced apoptosis,
whereas there is a significant decrease in the level of tyro-
sine phosphorylation at Tyr-15, an indirect result of cleav-
age and disruption of an upstream cdc2 kinase (Wee-1)
during apoptosis (Fig. 7 B, bottom panel). Dephosphor-
ylation of cdc2 (CDK1) activates its Histone H1 kinase ac-
tivity, as shown in Fig. 7 A (right side of panel). These re-
sults demonstrate that only SRPK1 and SRPK2 efficiently
utilize ASF/SF2 as an in vitro kinase substrate, and that en-
hanced phosphorylation of ASF/SF2 during apoptosis is at-
tributed to direct activation of SRPK1.
Cleavage of SRPK1 and SRPK2 Abrogates Their In Vitro
Kinase Activity. Finally, we examined whether SRPK1
and SRPK2 retained their kinase activity upon cleavage. It
has been reported that several kinases are activated upon
cleavage by caspases (for a review, see reference 30). We
assayed the kinase activity of SRPK1 and SRPK2 before or
after cleavage. Immunoprecipitation kinase assays for the
autoantigen DNA-PKCS, a kinase that is disrupted after
cleavage, were also performed as controls (4). Jurkat cells
were incubated with anti-Fas for 24 h, and kinases were
immunoprecipitated using anti-DNA-PKCS, anti-SRPK1,
or anti-SRPK2, respectively. Individual precipitates were
washed four times, incubated in individual reaction buffer
including 20  g of  -casein at 30 C for 15 min (DNA-
PKCS) or 25 pmoles of recombinant, bacterial ASF/SF2 at
30 C for 30 min (SRPK1 and SRPK2). Proteins were sep-
arated by SDS-PAGE, transferred to nitrocellulose, and
detected by autoradiography. The kinase activities were
determined by measuring the ability of the kinase to
phosphorylate   -casein or ASF/SF2, as indicated. As
shown in Fig. 8 A, full-length DNA-PKCS efficiently phos-
phorylates  -casein (lane 9), whereas the cleavage product
has dramatically decreased kinase activity (lane 12). The
small amount of phospho-casein (lane 12) is attributed to
the remaining, uncleaved DNA-PKCS (right panel, black
arrow). As shown in Fig. 8, B and C, full-length SRPK1
and SRPK2 phosphorylate ASF/SF2 (lane 8), while cleav-
age fragments of each kinase exhibit markedly decreased
activity (lane 11). This result suggests that SRPK1 is acti-
vated during apoptosis by some mechanism other than cas-
pase cleavage, and that SRPK1 kinase activity is disrupted
following caspase-mediated proteolysis.
Discussion
SR proteins such as ASF/SF2 and SC35 are essential
splicing factors in mammalian cells and are directly associ-
ated with components of the spliceosome (32). The U1-
snRNP and the U3-snoRNP are the major RNP autoanti-
gen targets in patients with SLE/MCTD and scleroderma,
respectively (1), and we have previously shown that multi-
ple different SR proteins associate with these two autoanti-
gen complexes during cell death (7, 8). SR proteins them-
selves have recently been identified as novel autoantigens in
connective tissue diseases (33). A striking finding in the dis-
covery that SR proteins are unique autoantigens is that au-
toantibodies preferentially recognize individual SR proteins
in a phosphorylation-dependent manner, with sera from
some patients exclusively recognizing phosphorylated SR
proteins, and others preferentially recognizing SR proteins
that had been stripped of phosphate residues by preincuba-
tion with phosphatase. Few studies have directly addressed
whether posttranslational modifications of antigens play a
direct role in recognition by autoimmune sera. In addition
to SR proteins, phosphorylated subunits of RNA poly-
merase I (but not isoforms lacking phosphate residues) are
recognized by human serum autoantibodies (34). Also, the
70-kD component of the U1-snRNP is preferentially rec-
ognized by SLE or scleroderma sera when the protein is
extracted from either apoptotic or oxidatively damaged
cells, respectively (35, 36).
We had previously demonstrated that phosphorylated
SR proteins reversibly associate with the U1-snRNP dur-
ing a variety of different apoptotic stimuli and this could be
inhibited by ectopic expression of the apoptosis inhibitory
protein bcl-2. Importantly, we also demonstrated that an
SR protein kinase activity was present in the coprecipi-
tated U1-snRNP autoantigen complexes, suggesting that
(i) the kinase responsible for phosphorylating SR proteins
in vivo and in vitro could be identified by carefully exam-
ining immunoprecipitates prepared using serum derived
from patients with SLE or MCTD and (ii) an SR protein
kinase could itself be an autoantigen. With regard to the
latter possibility, the results shown in Fig. 2 suggest other-
wise, as incubation of the immunoprecipitates with MgCl2
disrupts binding of SRPK1 to the U1-snRNP and pre-
vents SRPK1 coprecipitation. SRPK1 and SRPK2 are ef-
ficiently cleaved in vivo during apoptosis in a caspase-
dependent manner, and this cleavage is inhibited in vivo by
overexpression of either bcl-2 or bcl-xL. One of these ki-
nases, SRPK1, is clearly coprecipitated by all serum sam-
ples derived from patients with SLE or MCTD that were
tested. Analysis of available serum samples from our initial
report demonstrates that SRPK1 is also present in these
immunoprecipitates (Fig. 1, and unpublished data), sug-
gesting that SRPK1 is the autoantigen kinase observed in
our original reports (7, 8).
Several different subfamilies of SRPKs have been identi-
fied during the last decade, each of which were candidate
kinases in our studies. Clk/Sty kinases, of which there are
four main isoforms in humans, play important roles in reg-
ulation of alternative splicing (12). Since antibodies that
specifically recognize human Clk/Sty kinases have not
been developed, we have been unable to determine
whether any members of this kinase family may be associ-
ated with either SR proteins or the U1-snRNP. However,
previous experiments performed using cells labeled with
[35S] methionine did not identify prominent proteins in the
immunoprecipitates migrating by SDS-PAGE in the mo-
lecular weight range of Clk/Sty kinases (7, 8), arguing that
these kinases are not associated in abundance with the U1-
snRNP. cdc2 (CDK1) has also been reported to have SR
protein kinase activity, although we have found that ASF/
SF2 is a poor substrate for cdc2 (CDK1) in vitro (Fig. 7;
reference 20). Moreover, CDK1 is not coprecipitated by1222 Identification of an Autoantigen Kinase Signaling Pathway
human autoimmune sera (unpublished data). Similarly, to-
poisomerase I has previously been shown to be cleaved
during cell death, but it is a poor kinase in in vitro assays
(Fig. 7) (37), and it was not coprecipitated with the U1-
snRNP (Fig. 1, and unpublished data). Our inability to dem-
onstrate that topoisomerase I is capable of phosphorylating
ASF/SF2 in vitro is in contrast to the findings of Tazi’s lab-
oratory (19), and may in part be explained by the nature of
our assay, which used human autoimmune sera to precipi-
tate topoisomerase I before performing an in vitro kinase
assay directly on sepharose beads. Whether topoisomerase
I, which lacks consensus kinase domains found in most
protein kinases, is an important SRPK in vivo remains a
controversial question. It is important to note, however,
Figure 8. In vivo cleavage of DNA-PKCS, SRPK1, and SRPK2 results in decreased kinase activity of the kinase fragments. Jurkat cells were incubated
in the presence of anti-Fas for 24 h, solubilized in NP-40 lysis buffer, and precipitated using anti-DNA-PKCS, anti-SRPK1, or anti-SRPK2, respectively.
Kinase activities were assayed by immunoprecipitation assay as described in Materials and Methods. Each kinase activity was assayed using 0.5 mg of cy-
tosolic protein from the immunoprecipitations, and 20  g of  -casein (DNA-PKCS) or 25 pmoles of bacterial ASF/SF2 (SRPK1 and SRPK2), respec-
tively. Phosphorylation of substrates is demonstrated in the left panels (black arrow: ASF/SF2; white arrow:  -casein). Precipitated full-length protein
(black arrow) and cleavage product (arrow head) were analyzed by IP/Western blot in the right panels. The relative migration of molecular size markers
in kilodaltons is indicated on the left side of the panel. Phosphorylation of substrates is shown on the right side of the panel. Lanes are numbered at the
bottom of each panel.1223 Kamachi et al.
that topoisomerase I is itself a prominent autoantigen (Scl-
70) in patients with the diffuse form of scleroderma (1).
The mechanism(s) by which this autoantigen is targeted in
such patients remain obscure.
SRPK1 was first identified as an SR protein kinase that
copurified biochemically with components of the spliceo-
some (21, 38). A closely related homologue of SRPK1,
termed SRPK2, was soon identified (39). SRPK2 is 58%
homologous to SRPK1, differing only by the inclusion of
an additional domain of unknown function in the amino
terminus. Closely related SRPK1 and SRPK2 homologues
have been cloned and characterized in mice (40), and two
functional SRPK1 homologues have been identified in
budding yeast and fission yeast. The Saccharomyces cerevi-
siae SRPK1 homologue, Sky1p, regulates nuclear import
of the yeast SR-like protein Np13p (41–43). Another yeast
SRPK1 homologue, Dsk1, has been identified and charac-
terized in Schizosaccharomyces pombe (44). Interestingly, a
unique mammalian isoform of SRPK1 has recently been
identified (45). This SRPK1 isoform is produced by alter-
native splicing, encoding a protein with an insert of 171
amino acids in the amino terminus, proximal to one of the
kinase domains. Using this splice variant as bait in a yeast
two hybrid assay, Nikolakaki et al. demonstrated that the
novel isoform interacts specifically with Scaffold Attach-
ment Factor B (45). Our observation that SRPK1 migrates
significantly slower by SDS-PAGE in MCF7 cells may be
explained by such a mechanism, suggesting that a novel
SRPK1 isoform may exist in this cell line. Experiments de-
signed to address this possibility are in progress.
Detailed structural analysis of SRPK1 and SRPK2 has
not been reported. Their structure, as predicted from their
deduced amino acid sequence, suggests that cleavage of ei-
ther protein should disrupt kinase activity by preventing
the amino terminal and COOH terminal kinase domains
from interacting. Experiments shown in Fig. 8 support this
concept, since the kinase activity of a caspase cleavage frag-
ment of SRPK1 is markedly decreased. Cleavage of signal-
ing molecules by caspases or other proteases that are acti-
vated in response to cellular stressors has been suggested to
play an important role in many aspects of the apoptotic
phenotype (30). Kinases and other signaling molecules are
well positioned as caspase substrates to regulate the process
of cell death. Cleavage of signaling molecules can have a
variety of outcomes. For example, some kinases such as
SLK, PAK2, and P27Kip1 are activated or dysregulated
upon cleavage (46–48), whereas kinases such as the cata-
lytic subunit of DNA-PKCS and CaMK IV are permanently
inactivated upon cleavage (4, 49). Other kinases are relo-
calized to new intracellular compartments, e.g., relocaliza-
tion of fyn to the cytosol through removal of a palmitoyla-
tion and myristylation site by caspase-3, allowing the kinase
to interact with a novel substrate, Tctex-1 (50).
We provide data that the SR protein kinase activity asso-
ciated with SRPK1 is inactivated on caspase-mediated pro-
teolysis during cell death. One of the major functions pro-
posed for SRPK1 is to phosphorylate SR proteins, which
in turn regulates alternative splice site selection of a subset
of mRNA molecules, including the apoptosis regulatory
protein Ich-1 (51–53). Overexpression of SR proteins such
as ASF/SF2 alters splice site selection of several RNAs, in-
cluding Ich-1, and this correlates with resetting of the ap-
optotic threshold of transfected cells (52). Over 30 different
mRNAs have been identified that exist as two or more dif-
ferent splice variants, each with opposing apoptotic func-
tions (53). For example, alternative splicing of the mRNAs
encoding at least three different apoptosis regulatory mole-
cules has been recently shown to occur in vivo in dying
cells. Wotawa et al. demonstrated that procaspase 2L, a
proapoptotic isoform of caspase-2, is differentially down-
regulated in response to the apoptosis-inducing drug eto-
poside in tumor cells (54). Chalfant et al. showed that mRNAs
encoding caspase-9 and bcl-x are differentially spliced
in response to ceramide in A549 lung carcinoma cells and
that alternative splicing correlated with the phosphoryla-
tion state of SR proteins (55). Although they did not ad-
dress whether SRPKs might directly influence splice site
selection, their results suggested a role for the protein phos-
phatase-1 in the dephosphorylation of SR proteins (55),
which we have also observed at later time points (8, 9).
Therefore, it is highly likely that enzymes such as protein
phosphatase-1, SRPK1, and perhaps other SRPKs play a
critical role in determining whether an individual cell will
live or die in response to stressful stimuli by regulating rela-
tive levels of splice variants of such apoptosis regulatory
molecules. Other functions that could be indirectly attrib-
uted to SRPK1 through its kinase activity include regula-
tion of SR protein localization (41), shuttling of splicing
factors between the nucleus and cytoplasm (56), and
mRNA message stabilization (57). Experiments are in
progress to determine which of these functions might be
regulated by SRPKs during cell stress and apoptosis.
Caspases are the main executioners of the apoptotic
program. At the pinnacle of the caspase cascade are cas-
pases-8 and -9, which upon activation feed into the main
executioners, caspase-3 and -6. Caspase-8 is the major cas-
pase that is activated in response to death receptor–medi-
ated signals, while caspase-9 is the initiating caspase for
nonreceptor-mediated stimuli such as irradiation, growth
factor withdrawal, and chemotherapy, all of which are
regulated by mitochondrial-associated factors such as
APAF-1, cytochrome c, and bcl-2 (58). Our in vitro
caspase cleavage data (Fig. 3) and data published by others
demonstrates that three SRPKs (SRPK1, SRPK2, and to-
poisomerase I) are differentially cleaved by each of these
caspases (caspase-8, caspase-9, and caspases-3 and -6, re-
spectively) (19, 23). Because each of these SR protein ki-
nases are cleaved by key caspases in the cascade, our results
suggest that alternative splicing may play a critical role in
the sensing phase of cellular stress. mRNA splicing may
represent a largely unrecognized and unexplored posttran-
scriptional modification that determines cell fate in re-
sponse to environmental stimuli. Our results suggest that
SRPKs such as SRPK1 are activated during sublethal cell
stress (leading to alternative splicing of mRNAs such that
antiapoptotic isoforms such as bcl-xL and Ich1-  are pro-1224 Identification of an Autoantigen Kinase Signaling Pathway
duced). Caspase-mediated cleavage of SRPKs after lethal
stressors would then ensure that the apoptotic program is
faithfully executed in condemned cells.
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